Mitigare is a drug owned by Hikma International Pharmaceuticals Llc. It is protected by 5 US drug patents filed from 2015 to 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 22, 2033. Details of Mitigare's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9555029 | Methods of colchicine administration |
Aug, 2033
(8 years from now) | Active |
| US9675613 | Methods of colchicine administration |
Aug, 2033
(8 years from now) | Active |
| US8927607 | Methods of colchicine administration |
Aug, 2033
(8 years from now) | Active |
| US9399036 | Methods of colchicine administration |
Aug, 2033
(8 years from now) | Active |
| US9789108 | Methods of colchicine administration |
Aug, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mitigare's patents.
Latest Legal Activities on Mitigare's Patents
Given below is the list of recent legal activities going on the following patents of Mitigare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2024 | US9399036 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Apr, 2021 | US9789108 |
| Correspondence Address Change Critical | 06 Nov, 2020 | US9399036 |
| Correspondence Address Change Critical | 06 Nov, 2020 | US9675613 (Litigated) |
| Correspondence Address Change Critical | 06 Nov, 2020 | US9789108 |
| Correspondence Address Change Critical | 06 Nov, 2020 | US9555029 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Aug, 2020 | US9675613 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Jul, 2020 | US9555029 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2019 | US9399036 |
| Recordation of Patent Grant Mailed Critical | 17 Oct, 2017 | US9789108 |
US patents provide insights into the exclusivity only within the United States, but Mitigare is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mitigare's family patents as well as insights into ongoing legal events on those patents.
Mitigare's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Mitigare's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 22, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Mitigare Generic API suppliers:
Colchicine is the generic name for the brand Mitigare. 12 different companies have already filed for the generic of Mitigare, with Zydus Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Mitigare's generic
How can I launch a generic of Mitigare before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Mitigare's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Mitigare's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Mitigare -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.6 mg | 10 Jun, 2016 | 1 | 29 Nov, 2018 | 22 Aug, 2033 | Eligible |
Alternative Brands for Mitigare
Mitigare which is used for preventing gout flares., has several other brand drugs in the same treatment category and using the same active ingredient (Colchicine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Takeda Pharms Usa |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Colchicine. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Colchicine, Mitigare's active ingredient. Check the complete list of approved generic manufacturers for Mitigare
About Mitigare
Mitigare is a drug owned by Hikma International Pharmaceuticals Llc. It is used for preventing gout flares. Mitigare uses Colchicine as an active ingredient. Mitigare was launched by Hikma Intl Pharms in 2014.
Approval Date:
Mitigare was approved by FDA for market use on 26 September, 2014.
Active Ingredient:
Mitigare uses Colchicine as the active ingredient. Check out other Drugs and Companies using Colchicine ingredient
Treatment:
Mitigare is used for preventing gout flares.
Dosage:
Mitigare is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.6MG | CAPSULE | Prescription | ORAL |